idente catalogue - hospital innovations · hospital innovations is comprised of six distinct ......

iDente Catalogue

Abou tHOSPITAL INNOVATIONS

| 1

Since 2008, Hospital Innovations has been supplying a growing range of specialist products for use in orthopaedic and corrective surgery; with an emphasis on innovation and quality.

Hospital Innovations is a Human Tissue Authority (HTA) licensed establishment, allowing us to store and distribute human allograft tissue and bone with the support of our valued international partners; two of the world’s leading tissue banks.

Hospital Innovations is comprised of six distinct divisions; each with a unique focus, but all operating under Hospital Innovations’ aim of delivering innovative, safe and effective solutions.

Across all divisions, Hospital Innovations endeavour to responsibly deliver outstanding customer support within our service levels and product range. Our detailed, consultative approach to service support and training is the cornerstone of Hospital Innovations’ philosophy.

Safety, effectiveness and consistency of quality are Hospital Innovations’ core values; with a mindful and sensitive appreciation that the end-user is a person in need.

“Strong commitment to healthcare innovation”

“Consistent delivery of outstanding customer service”

“Dedicated to providing safe and effective treatment options for your patient”

DRIVING THE

FUTURE

| 2

INTRODUCINGiDENTE

| 3

With innovation at the foundation of its success, Hospital Innovations now provide a range of dental products to assist surgical procedures.

Hospital Innovations’ iDente catalogue includes an extensive array of both allograft and synthetic bone substitution products, demineralised bone matrices and HA enriched viscosupplementation injections.

The iDente division is committed to providing both innovative and cost effective dental solutions to its customers.

Hospital Innovations’ dental portfolio is designed to assist surgeons with a multitude of dental procedures such as sinus lifts, ridge augmentations and the repair of periodontal defects. Products are available in a range of sizes to accommodate various applications and are packaged with a long shelf life.

About iDente

Applications

Free

ze-d

ried

Cru

shed

Can

cello

us

Chi

ps

Can

cello

us C

ubes

Min

eral

ised

Can

cello

us

Par

ticu

late

Free

ze-d

ried

Co

rtic

oca

ncel

lous

C

hip

s

Dem

iner

alis

ed C

ort

ical

Par

ticu

late

w

ith

PAD

™

Min

eral

ised

Co

rtic

al P

arti

cula

te

Min

eral

ised

Co

rtic

oca

ncel

lous

P

arti

cula

te M

ix

Op

tium

® D

BM

Nan

oB

one

®

HYA

LOS

S®

Mat

rix

OrA

CE

LL®

OR

TH

OV

ISC

® m

ini

Periodontal Defects

Ridge Augmentation

Extraction Site Preservation

Sinus Grafting

Void/Socket Filling

TMJ Pain Relief

Figure 1. Comparison of Appropriate Uses for iDente Products

| 4

Each of Hospital Innovations’ human allograft products provide a guaranteed Sterility Assurance Level (SAL) of 10-6, the same as that for medical devices. This means that no more than a single viable particle in 1 million units could potentially be compromised, providing exceptional product reliability[1].

This level of sterility is achieved via a patented cleaning and disinfection process called Allowash XG®. This process removes more than 99% of bone marrow and blood elements from the bone matrix, rendering it sterile[1]. Allowash

XG® follows a six stage process to ensure bioimplant safety without compromising the biomechanical or biochemical properties of the tissue[2].

Hospital Innovations is the largest independent private Human Tissue Bank in the UK, fully licensed and regulated by the Human Tissue Authority. Available as both mineralised and demineralised, our cortical and cancellous allografts provide an osteoconductive scaffold for bone ingrowth and rapid remodelling with the patient’s own bone.

Products are available in a range of sizes in either cube or particulate formulation to accommodate an array of dental procedures.

Human Allograft

Sterility

Figure 2. Before Allowash XG® Sterilisation [2]

Figure 3. After Allowash XG® Sterilisation [2]

OraGRAFT®. Freeze-dried Cubes and Particulate.

| 5

Demineralised Bone Matrix

To place an order, please contact us:

Phone: 01443 719 555Fax: 01443 719 560E-mail: [email protected]

Demineralisation Process

Optium® DBM. Setting the Standard for DBM Performance. Optium® DBM has both osteoconductive and osteoinductive properties that provide a natural architecture with increased surface area to encourage cellular attachment[3].

A ready to use product with consistent handling properties, Optium® DBM is available in putty or gel formations and has proven clinical results for any bone filling application[3].

Demineralisation is achieved when the residual calcium level is below 8%. However, the PAD™ demineralisation process is able to consistently target a 1-4% residual calcium range, which studies have shown provides the most osteoconductive potential[4]. The PAD™ process also eliminates both over and under demineralisation, which can have a detrimental effect on osteoconductive potential and performance.

| 6

Synthetic Grafting

NanoBone®. The Synthetic Bone Grafting Alternative.

NanoBone® is a synthetic bone grafting material that is ready to use with no preparation time and available in granulate, block and putty variations. Its nanocrystalline hydroxyapatite nanostructure enhances angiogenesis, thus allowing for rapid bone formation in as little as 3 months[5]. This structure improves porosity, providing an increased surface area when compared to a bovine equivalent.As blood populates the porous nanostructure, NanoBone® is recognised as a material familiar to the body, preventing an immunological response.It also permits for complete remodelling and resorption due to its osteoclastic characteristics. This allows NanoBone® to be completely remodelled and replaced with bone[6].

Recommendations for Use

Sinus Lifts | Socket Preservation | Lateral Augmentation

Intraosseous Defects | Furcations

Cystectomy / Root End Surgery

Granulate

Lateral Augmentation Intraosseous Defects

Bone Void / Gap FillerIntraosseous Defects

Block

Putty

| 7

HYALOSS® Matrix. Bioactive Hyaluronic Acid Matrix.

HYALOSS® Matrix provides a gradual release of pure hyaluronic acid (HA) which promotes the activation and stimulation of fibroblasts and endothelial cells. This helps to boost the physiological regeneration of natural, highly vascularised tissue[7].When hydrated, it forms a gel like substance which improves both the handling and retention of a bone graft at the defected site without compromising the osseous regeneration potential of the graft[7].Intended as an adjunct of the grafting process, HYALOSS® Matrix can be used as part of any regenerative therapy.

• Promotes bone graft application• Easy handling• Conforms to any defect type• Biocompatible and naturally absorbed• Natural, non-animal sourced

Hyaluronic Acid Carrier

The HYALOSS® Matrix Advantage

• Mix fibres with sterile saline solution or patients own blood to form a gel

• Mix the gel with bone particulate such as our OraGRAFT® allograft (pg. 5) or NanoBone® synthetic (pg. 7) to create a paste

• Apply to the defected area

| 8

How to Use

Figure 4. Case Study of Missing Lateral Incisor Implant Surgery Using OrAGRAFT® and OrACELL® [8]

Decellularised Dermis

OrACELL®. A High Performance Acellular Dermal Matrix.

Case Study

Four weeks after implantation

A surgery performed for implant placement at the sites of congenitally missing lateral incisors. A combination of OraGraft® mineralised cortical particulate and OrACELL® decellularised dermis were placed on the labial to correct the thin bone support and to increase the soft tissue profile in these areas.

OrACELL® is a superior allograft dermis which is ready to use off the shelf, requiring no surgical preparation time. Its efficient handling properties, pull out strength and load to failure make OrACELL® ideal for dental applications.

Through the use of MATRACELL™ technology, more than 97% of DNA from the dermal matrix is removed[8]. This renders the dermis acellular without compromising the biological or biomechanical properties of the tissue.

Hospital Innovations’ acellular dermal matrix is intended for use in conjunction with bone regeneration and oral soft tissue correction procedures.

| 9

Proven to provide long

lasting TMJ pain relief after one

injection

Viscosupplementation

Hospital Innovations also offer a HA enriched viscosupplementation injection, aimed at targeting small joints such as the TMJ. With the highest HA concentration available on the market, ORTHOVISC® mini is a safe and reliable alleviator of persistent joint pain.

Product Features

• Specially designed for small joints• Created from ultra-pure, natural hyaluronan• Provides pain relief from symptoms

of osteoarthritis • High molecular weight• Highest HA concentration of any

small injection

Improving TMJ Function• A single injection provided at least 6

months of consistent benefit• Proven safe injection procedure• Reduction in painful symptoms

including;◊ 22% improvement in mouth

function◊ 28% decrease in lower jaw pain◊ 24% decrease in TMJ palpation

pain[11]

Figure 5. Comparison of Viscosity and Molecular Weight of Hyaluronan Properties [9]

Figure 6. Improvement in Mean Total Anamnestic Score between Hyaluronic Acid and a Placebo [10]

| 10

Ordering Information

Product No. Product DescriptionCH20002 Freeze-dried, Crushed Cancellous Chips: 1-4mm, 15cc

CH20004 Freeze-dried, Crushed Cancellous Chips: 1-4mm, 30cc















CANCELLOUS

Freeze-dried Chips

Product No. Product DescriptionAD10001 Freeze-dried Cancellous Cubes: 15x15x15mm

AD10002 Freeze-dried Cancellous Cubes: 15x15x8mm



CH20100 Freeze-dried Cancellous Cubes: 5cc (5x5x5mm)

CH20101 Freeze-dried Cancellous Cubes: 15cc (5x5x5mm)

Freeze-dried Cubes and Blocks

| 11

Product No. Product DescriptionAD10040 Demineralised Cortical Particulate with PAD™: 250-1000 microns, 0.25cc

AD10041 Demineralised Cortical Particulate with PAD™: 250-1000 microns, 0.5cc




CORTICAL

Freeze-dried Demineralised Particulate

Product No. Product DescriptionAD10045 Mineralised Cortical Particulate: 250-1000 microns, 0.25cc

AD10046 Mineralised Cortical Particulate: 250-1000 microns, 0.5cc




Freeze-dried Mineralised Particulate

Product No. Product DescriptionAD10050 Mineralised Cancellous Particulate: 250-1000 microns, 0.5cc

AD10051 Mineralised Cancellous Particulate: 250-1000 microns, 1cc


AD10053 Mineralised Cancellous Particulate: 1000-2000 microns, 0.5cc



Mineralised Particulate

Product No. Product DescriptionCH20102 Freeze-dried Cancellous Cubes: 20cc (8 Cubes: 10x10x10mm)

CH20103 Freeze-dried Cancellous Cubes: 30cc (12 Cubes: 10x10x10mm)

CH20104 Freeze-dried Cancellous Cubes: 40cc (16 Cubes: 10x10x10mm)

CH50130 Freeze-dried Cancellous Blocks: 20x20x30mm

| 12

Product No. Product DescriptionAD10056 Mineralised Corticocancellous Particulate Mix: 250-1000 microns, 0.50cc

AD10057 Mineralised Corticocancellous Particulate Mix: 250-1000 microns, 1.0cc

AD10058 Mineralised Corticocancellous Particulate Mix: 250-1000 microns, 2.0cc

Mineralised Particulate

Product No. Product DescriptionNB50001 NanoBone® Putty: 0.5ml

NB50002 NanoBone® Putty: 1ml

NB50003 NanoBone® Putty: 2.5ml



NB50006 NanoBone® Granules: 0.6x2mm, 0.6ml

NB50007 NanoBone® Granules: 0.6x2mm, 5x0.6ml





NB50012 NanoBone® Granules: 0.6x2mm, 5ml

NB50013 NanoBone® Granules: 1x2mm, 1.2ml

NB50014 NanoBone® Granules: 1x2mm, 5x1.2ml

NB50015 NanoBone® Granules: 1x2mm, 2.4ml

NANOBONE®

Product No. Product DescriptionCH50042 Freeze-dried, Corticocancellous Chips: 1-8mm, 10cc

CH50043 Freeze-dried, Corticocancellous Chips: 1-8mm, 20cc






CORTICOCANCELLOUS

Freeze-dried Chips

| 13

Product No. Product DescriptionDE50090 DBM Optium Gel: 1cc

DE50091 DBM Optium Gel: 5cc

DE50092 DBM Optium Gel: 10cc

DE50093 DBM Optium Putty: 1cc

DE50094 DBM Optium Putty: 2.5cc



OPTIUM DBM®

Product No. Product DescriptionIN40060 HYALOSS™ Matrix: Box of 4 Sterile Blister Packs

HYALOSS® MATRIX

Product No. Product DescriptionAD10100 OrACELL® Decellularised Dermis with MATRACELL™: 15x20mm, 0.76-1.25mm thick

AD10101 OrACELL® Decellularised Dermis with MATRACELL™: 20x40mm, 0.76-1.25mm thick







ORACELL®

Product No. Product DescriptionIN40002 Orthovisc® Mini

ORTHOVISC® MINI

| 14

Product No. Product DescriptionNB50016 NanoBone® Granules: 1x2mm, 5x2.4ml

NB50017 NanoBone® Granules: 1x2mm, 5ml

NB50018 NanoBone® Granules Block: 5x10x15mm

Enquiries

Ordering

For further information regarding any of our products, please feel free to contact our Customer Service Team.

Customer Service TeamTel: 01443 719 555E-mail: [email protected]

To place an order, please contact us by phone, fax or e-mail:

Tel: 01443 719 555Fax: 01443 719 560E-mail: [email protected]

Hospital Innovations LtdConcept HouseTalbot Green Business ParkPontyclunCF72 9FG

www.hospitalinnovations.com

References

1. LifeNet Health. (2013). CMF & Dental Allograft Solutions: Saving Lives, Restoring Health.2. LifeNet Health. (2009). Allowash XG®: Allograft Bio-Implant Sterilisation Technology.3. LifeNet Health. (2013). Optium DBM Putty.4. LifeNet Health. (2013). Bio-Implant Reference Manual.5. Meier, J., Heine, M. and Wolf, E. (2007). Shortening Therapy Protocols by using the Nanocrystalline Bone Substitute NanoBone® for Sinus Floor

Elevations and Augmentation of other Bone Defects. European Association for Osseointegration (EAO): Barcelona.6. Artoss. Bone Formation in a New Dimension: Information on the Synthetic Bone Grafting Material NanoBone®.7. Anika Therapeutics. (2015). Hyaloss® Matrix: Bioactive Hyaluronic Matrix for Bone Particulate Grafts in Regenerative Therapy.8. LifeNet Health. (2013). OrACELL®: Decellularised Dermis for Maxillofacial Applications.9. Anika Therapeutics. Orthovisc® mini: A Targeted Treatment for Small Joint Pain.10. Bertolami, C., Gay, T., Clark, G., Rendell, J., Shetty, V., Changrui, L. and Swann, D. (1993). Use of Sodium Hyaluronate in Treating

Temporomandibular Joint Disorders: A Randomised, Double Blind, Placebo Controlled Clinical Trial. Journal of Oral and Maxillofacial Surgery. 51, 232 - 242.

11. Orkun, F., Aytac, F. and Evcik, D. (2000). Clinical Use of Sodium Hyaluronate in treating Temporomandibular Joint Dysfunction. Medical Physics. 3(1).

| 15

idente catalogue - hospital innovations · hospital innovations is comprised of six distinct ......

Documents